Agenus Inc. (AGEN)
| Market Cap | 129.18M +68.0% |
| Revenue (ttm) | 123.87M +24.5% |
| Net Income | 64.39M |
| EPS | 1.93 |
| Shares Out | 41.54M |
| PE Ratio | 1.61 |
| Forward PE | 11.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 901,310 |
| Open | 3.300 |
| Previous Close | 3.160 |
| Day's Range | 3.050 - 3.360 |
| 52-Week Range | 2.710 - 7.340 |
| Beta | 1.60 |
| Analysts | Strong Buy |
| Price Target | 15.50 (+398.39%) |
| Earnings Date | May 11, 2026 |
About AGEN
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte ... [Read more]
Financial Performance
In 2025, Agenus's revenue was $114.20 million, an increase of 10.37% compared to the previous year's $103.46 million. Losses were -$101,000, -99.96% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 398.39% from the latest price.
News
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AI--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new retrospective data showing that Noetik's artificial intelligenc...
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #ASCO2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study ...
Agenus announces publication of Phase 1b BOT+BAL data
Agenus (AGEN) announced the publication of Phase 1b data evaluating botensilimab, an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab, an anti-PD-1 antibody, in patients with treatmen...
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), a...
Agenus Proxy statement: Proxy filing
Agenus filed a proxy statement on May 13, 2026, providing details for shareholder voting and corporate governance matters.
Agenus reports Q1 revenue $33.7M vs. $24.1M last year
“First quarter 2026 was a defining quarter for Agenus (AGEN) and for BOT and BAL,” said Garo H. Armen, Ph.D., Chairman and Chief Executive Officer of Agenus. “We saw continued…
Agenus provides 2026 strategic priorities
The company said, “2026 Strategic Priorities: Support responsible authorized access through France’s AAC framework and paid named-patient programs in select countries, with BAP Pharma serving as globa...
Agenus announces conclusion of SEC investigation with no enforcement action
The company said, “On May 4, 2026, the U.S. Securities and Exchange Commission informed Agenus (AGEN) that it has concluded its investigation as to the Company and does not intend…
Agenus Earnings release: Q1 2026
Agenus released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Agenus Quarterly report: Q1 2026
Agenus has published its Q1 2026 quarterly earnings report on May 11, 2026.
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BATTMAN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the first quarter ended March 31, 2026, a...
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its first quarter 2026 financial re...
Agenus Proxy statement: Proxy filing
Agenus filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AI--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that four abstracts highlighting botensilimab (BOT), alone or in co...
Agenus appoints BAP Pharma as global partner for BOT+BAL access programs
Agenus (AGEN) and BAP Pharma announced the exclusive appointment of BAP Pharma as Agenus’ global partner for botensilimab plus balstilimab authorized global access programs. The partnership supports c...
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
LEXINGTON, Mass. & MARLOW, England--(BUSINESS WIRE)---- $AGEN #AAC--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial sup...
Agenus Proxy statement: Proxy filing
Agenus filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Agenus reports Phase 2 results from BOT and BAL with agenT-797
Agenus (AGEN) announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating botensilimab (BOT) and balstilimab (BAL) in combination with agenT-7...
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memoria...
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial condu...
Agenus announces first patient enrolled in Phase 3 BATTMAN trial of BOT+BAL
Agenus (AGEN) announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN trial. This study is evaluating Agenus’ immunotherapy combination of botensilimab plus balstilim...
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global ph...
Agenus Transcript: AGM 2026
The meeting highlighted strong clinical progress and growing global demand for immunotherapy in MSS colorectal cancer, with $3.2 million in Q4 revenues from access programs. Leadership outlined regulatory and commercial strategies for 2026, while addressing capital needs and market valuation challenges.
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continued pr...
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR26--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating b...